Glaukos Corp (GKOS) Shares Fall 5.2% -- What GF Score of 77 Tell
Glaukos Corp (GKOS) shares fell 5.2% to $170.38, within a 52-week range of $73.16 to $191.62. The stock is up 94.7% year-to-date but has declined 5.5% in the past week and 6.1% in the past month. GuruFocus values GKOS at $151.61, suggesting it is 12.4% overvalued. The company has a GF Score of 77/100, indicating above-average performance. Insiders sold $67.6M in shares over the past year with no buying.
How this was made
The 30-second read
Why it matters
Overvaluation and insider selling may pressure the stock further; no new corporate event disclosed.
Market read
The article provides a valuation recap and insider sell data, offering limited actionable insight.
What to watch
Potential pipeline progress or upcoming regulatory approvals not covered in the article.
Background
GuruFocus valuation summary and insider activity for Glaukos Corp (GKOS).
Ticker impact
Shares fell 5.2% on Sep 10 to $170.38, overvalued vs GF estimate and $67.6M insider sales in past 12 months.
Further downside pressure likely if overvaluation persists.
Overvaluation and large insider sell signal reduced confidence; no new catalyst to reverse trend.
Market effects
Highlights valuation concerns for the ophthalmic device sector.
Limited to US biotech/medical device investors.
Minimal global impact.
Counterpoint
Some investors may view the 77 GF Score as a buying opportunity despite short‑term price weakness.
Key entities
- companyGlaukos Corp
US‑listed ophthalmic device maker (ticker GKOS).
